Balyasny Asset Management
CRDF icon

Balyasny Asset Management’s Cardiff Oncology CRDF Stock Holding History

Balyasny Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-290
Closed -$97K – 1203
2016
Q1 		$97K Buy
+290
New +$98.7K ﹤0.01% 1202

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's CRDF Position: Q2 2016 in Review

Balyasny Asset Management sold out of Cardiff Oncology (CRDF) in Q2 2016, closing a stake of 290 shares — an estimated $97K sold.

Balyasny Asset Management first reported a position in CRDF in Q1 2016 and held it in 1 quarter. The position peaked at $97K in Q1 2016. 66 funds tracked by Wall St. Rank hold CRDF as of Q2 2016.

  • Balyasny Asset Management reported no remaining Cardiff Oncology position as of Q2 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 290 Cardiff Oncology shares in Q2 2016, an estimated $97K.
  • Balyasny Asset Management first reported a position in Cardiff Oncology in Q1 2016 and held it in 1 quarter.
  • Balyasny Asset Management's Cardiff Oncology position peaked at $97K in Q1 2016.
  • 66 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2016.

Based on Balyasny Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.